Diabetes and beta cell function: From mechanisms to evaluation and clinical implications

Biochemia Medica

Volumn 23, Issue 3, 2013, Pages 266-280

  Cernea, Simona ^a   Dobreanu, Minodora ^a,b  

^a Emergency Clinical Hospital   (Romania)

^b UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Diabetes mellitus; Hyperglycemia; Pancreatic beta cells

Indexed keywords

ACETYLSALICYLIC ACID; ADIPOCYTOKINE; AMYLIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CASPASE 3; CXCL1 CHEMOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; FAS LIGAND; FATTY ACID; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INTERLEUKIN 6; LEPTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PREPROINSULIN; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SPHINGOSINE 1 PHOSPHATE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

AUTOIMMUNITY; CELL FUNCTION; DIABETES MELLITUS; DRUG MEGADOSE; GENE EXPRESSION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOGENESIS; REVIEW;

ANIMALS; AUTOIMMUNITY; DIABETES MELLITUS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LIPIDS; RISK FACTORS;

EID: 84885063145     PISSN: 13300962     EISSN: None     Source Type: Journal    
DOI: 10.11613/BM.2013.033     Document Type: Review

References (100)

1. Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A. Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 2001;50(Suppl 1):8154-9. http://dx.doi.org/10.2337/diabetes.50.2007.S154.
2. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965;14:619-33.
3. Pinhas-Hamiel O, Zeitler P. Clinical presentation and treatment of type 2 diabetes in children. Pediatr Diabetes 2007;8 Suppl 9:16-27. http://dx.doi.org/10.1111/j.1399-5448.2007.00330.x.
4. Brooks-Worrell B, Palmer JP. Is diabetes mellitus a continuous spectrum? Clin Chem 2011;57:158-61. http://dx.doi.org/10.1373/clinchem.2010.148270.
5. Sherry NA, Tsai EB, Herold KC. Natural history of beta-cell function in type 1 diabetes. Diabetes 2005;54 Suppl 2:S32-9. http://dx.doi.org/10.2337/diabetes.54.suppl_2.S32.
6. Fourlanos S, Harrison LC, Colman PG. The accelerator hypothesis and increasing incidence of type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2008;15:321-5. http://dx.doi.org/10.1097/MED.0b013e3283073a5a.
7. Wilkin TJ. The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type I as well as type II diabetes. Int J Obes (Lond) 2009;33:716-26. http://dx.doi.org/10.1038/ijo.2009.97.
8. Nokoff NJ, Rewers M, Cree Green M. The interplay of autoimmunity and insulin resistance in type 1 diabetes. Discov Med 2012;13:115-22.
9. Schofield CJ, Sutherland S. Disordered insulin secretion in the development of insulin resistance and Type 2 diabetes. Diabet Med 2012;29:972-9. http://dx.doi.org/10.1111/j.1464-5491.2012.03655.x.
10. Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005;54 Suppl 2:S97-107. http://dx.doi.org/10.2337/diabetes.54.suppl_2.S97
11. Wajchenberg B. Beta-cell failure in diabetes and preservation by clinical treatment. Endocrine Rev 2007;28:187-218. http://dx.doi.org/10.1210/10.1210/er.2006-0038.
12. Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004;53 Suppl 1:S119-24. http://dx.doi.org/10.2337/diabetes.53.2007.S119.
13. van Raalte DH, Diamant M. Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy? Diabetes Res Clin Pract 2011;93 Suppl 1:S37-46. http://dx.doi.org/10.1016/S0168-8227(11)70012-2.
14. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003;52:581-7. http://dx.doi.org/10.2337/diabetes.52.3.581.
15. Poitout V, Robertson RP. Glucolipotoxicity: Fuel excess and β-cell dysfunction. Endocr Rev 2008;29:351-66. http://dx.doi.org/10.1210/er.2007-0023.
16. Kim JW, Yoon KH. Glucolipotoxicity in pancreatic β-Cells. Diabetes Metab J 2011;35:444-50. http://dx.doi.org/10.4093/dmj.2011.35.5.444.
17. Poitout V, Olson LK, Robertson RP. Chronic exposure of betaTC-6 cells to supraphysiologic concentrations of glucose decreases binding of the RIPE3b1 insulin gene transcription activator. J Clin Invest 1996;97:1041-6. http://dx.doi.org/10.1172/JCI118496.
18. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006;116:1802-12. http://dx.doi.org/10.1172/JCI29103.
19. Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008;29:42-61. http://dx.doi.org/10.1210/er.2007-0015.
20. Shin CS, Moon BS, Park KS, Kim SY, Park SJ, Chung MH, et al. Serum 8 hydroxy-guanine levels are increased in diabetic patients. Diabetes Care 2001;24:733-7. http://dx.doi.org/10.2337/diacare.24.4.733.
21. Sakuaba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S. Reduced β-cell mass and expression of oxidative stress related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia 2002;45:85-96. http://dx.doi.org/10.1007/s125-002-8248-z.
22. Del Guerra S, Lupi R, Marselli L, Masini M, Bugliani M, Sbrana S, et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 2005;54:727-35. http://dx.doi.org/10.2337/diabetes.54.3.727.
23. Kawahito S, Kitahata H, Oshita S. Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J Gastroenterol 2009;15:4137-42. http://dx.doi.org/10.3748/wjg.15.4137.
24. Acharya JD, Ghaskadbi SS. Islets and their antioxidant defense. Islets 2010;2:225-35. http://dx.doi.org/10.4161/isl.2.4.12219.
25. Leibowitz G, Bachar E, Shaked M, Sinai A, Ketzinel-Gilad M, Cerasi E, et al. Glucose regulation of β-cell stress in type 2 diabetes. Diabetes Obes Metab 2010;12 Suppl 2:66-75. http://dx.doi.org/10.1111/j.1463-1326.2010.01280.x.
26. Kaufman RJ, Back SH, Song B, Han J, Hassler J. The unfolded protein response is required to maintain the integrity of the endoplasmic reticulum, prevent oxidative stress and preserve differentiation in β-cells. Diabetes Obes Metab 2010;12 Suppl 2:99-107. http://dx.doi.org/10.1111/j.1463-1326.2010.01281.x.
27. Eriksson JW. Metabolic stress in insulin's target cells leads to ROS accumulation-a hypothetical common pathway causing insulin resistance. FEBS Lett 2007;581:3734-42. http://dx.doi.org/10.1016/j.febslet.2007.06.044.
28. Lu H, Koshkin V, Allister EM, Gyulkhandanyan AV, Wheeler MB. Molecular and Metabolic Evidence for Mitochondrial Defects Associated With β-Cell Dysfunction in a Mouse Model of Type 2 Diabetes. Diabetes 2010;59:448-59. http://dx.doi.org/10.2337/db09-0129.
29. Ma Z, Wirström T, Borg LA, Larsson-Nyrén G, Hals I, Bondo-Hansen J, et al. Diabetes reduces β-cell mitochondria and induces distinct morphological abnormalities, which are re-producible by high glucose in vitro with attendant dysfunction. Islets 2012;4:233-42. http://dx.doi.org/10.4161/isl.20516.
30. + homeostasis. Diabetes Obes Metab 2012;14 Suppl 3:136-42. http://dx.doi.org/10.1111/j.1463-1326.2012.01649.x.
31. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002;110:851-60.
32. DeFronzo RA. Dysfunctional fat cells, lipotoxicity and type 2 diabetes. Int J Clin Pract Suppl 2004;143:9-21. http://dx.doi.org/10.1111/j.1368-504X.2004.00389.x.
33. Deguil J, Pineau L, Rowland Snyder EC, Dupont S, Beney L, Gil A, et al. Modulation of lipid-induced ER stress by fatty acid shape. Traffic 2011;12:349-362. http://dx.doi.org/10.1111/j.1600-0854.2010.01150.x.
34. Prentki M, Joly E, El-Assaad W, Roduit R. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes 2002;51 Suppl 3:S405-13. http://dx.doi.org/10.2337/diabetes.51.2007.S405.
35. Yaney GC, Corkey BE. Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia 2003;46:1297-312. http://dx.doi.org/10.1007/s00125-003-1207-4.
36. Cnop M, Hannaert JC, Grupping AY, Pipeleers DG. Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 2002;143:3449-53. http://dx.doi.org/10.1210/en.2002-220273.
37. Abderrahmani A, Niederhauser G, Favre D, Abdelli S, Ferdaoussi M, Yang JY, et al. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia 2007;50:1304-14. http://dx.doi.org/10.1007/s00125-007-0642-z.
38. Kruit JK, Wijesekara N, Westwell-Roper C, Vanmierlo T, de Haan W, Bhattacharjee A, et al. Loss of both ABCA1 and ABCG1 results in increased disturbances in islet sterol homeostasis, inflammation, and impaired β-cell function. Diabetes 2012;61:659-64. http://dx.doi.org/10.2337/db11-1341.
39. Rütti S, Ehses JA, Sibler RA, Prazak R, Rohrer L, Georgopoulos S, et al. Low-and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology 2009;150:4521-30. http://dx.doi.org/10.1210/en.2009-0252.
40. Brooks-Worrell B, Palmer JP. Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clin Exp Immunol 2012;167:40-6. http://dx.doi.org/10.1111/j.1365-2249.2011.04501.x.
41. Brooks-Worrell BM, Reichow JL, Goel A, Ismail H, Palmer JPP. Identification of autoantibody-negative autoimmune type 2 diabetes patients. Diabetes Care 2011;34:168-73. http://dx.doi.org/10.2337/dc10-0579.
42. Genovese S, Bazzigaluppi E, Gonçalves D, Ciucci A, Cavallo MG, Purrello F, et al. Clinical phenotype and beta-cell autoimmunity in Italian patients with adult-onset diabetes. Eur J Endocrinol 2006;154:441-7. http://dx.doi.org/10.1530/eje.1.02115.
43. Donath MY, Størling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T. Cytokines and beta-cell biology: from concept to clinical translation. Endocr Rev 2008;29:334-50. http://dx.doi.org/10.1210/er.2007-0033.
44. Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes. Diabetologia 2001;44:914-22. http://dx.doi.org/10.1007/s001250100548.
45. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009;24:325-31. http://dx.doi.org/10.1152/physiol.00032.2009.
46. Paroni F, Domsgen E, Maedler K. CXCL10a path to β-cell death. Islets 2009;1:256-9. http://dx.doi.org/10.4161/isl.1.3.9110.
47. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009;94:3171-82. http://dx.doi.org/10.1210/jc.2008-2534.
48. Dula SB, Jecmenica M, Wu R, Jahanshahi P, Verrilli GM, Carter JD, et al. Evidence that low-grade systemic inflammation can induce islet dysfunction as measured by impaired calcium handling. Cell Calcium 2010;48:133-42. http://dx.doi.org/10.1016/j.ceca.2010.07.007.
49. Dunmore SJ, Brown JE. The role of adipokines in β-cell failure of type 2 diabetes. J Endocrinol 2013;216:T37-45. http://dx.doi.org/10.1530/JOE-12-0278.
50. Cai K, Qi D, Wang O, Chen J, Liu X, Deng B, et al. TNF-α acutely upregulates amylin expression in murine pancreatic beta cells. Diabetologia 2011;54:617-26. http://dx.doi.org/10.1007/s00125-010-1972-9.
51. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012;55:2319-26. http://dx.doi.org/10.1007/s00125-012-2598-x.
52. Wijesekara N, Krishnamurthy M, Bhattacharjee A, Suhail A, Sweeney G, Wheeler MB. Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. J Biol Chem 2010;285:33623-31. http://dx.doi.org/10.1074/jbc.M109.085084.
53. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011;17:55-63. http://dx.doi.org/10.1038/nm.2277.
54. Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004;89:3629-43. http://dx.doi.org/10.1210/jc.2004-0405.
55. Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev 2011;91:795-826. http://dx.doi.org/10.1152/physrev.00042.2009.
56. Clark A, Nilsson MR. Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes? Diabetologia 2004;47:157-69. http://dx.doi.org/10.1007/s00125-003-1304-4.
57. Anguiano M, Nowak RJ, Lansbury PT Jr. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 2002;41:11338-43. http://dx.doi.org/10.1021/bi020314u.
58. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 2010;11:897-904. http://dx.doi.org/10.1038/ni.1935.
59. Jurgens CA, Toukatly MN, Fligner CL, Udayasankar J, Subramanian SL, Zraika S, et al. β-cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 2011;178:2632-40. http://dx.doi.org/10.1016/j.ajpath.2011.02.036.
60. Vilsbøll T. The effects of glucagon-like peptide-1 on the beta cell. Diabetes Obes Metab 2009;11(Suppl 3):11-8. http://dx.doi.org/10.1111/j.1463-1326.2009.01073.x.
61. Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes Care 2011;34 Suppl 2:S264-71. http://dx.doi.org/10.2337/dc11-s223.
62. Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first-and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 2003;26:791-8. http://dx.doi.org/10.2337/diacare.26.3.791.
63. Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, et al. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005;90:5991-7. http://dx.doi.org/10.1210/jc.2005-1093.
64. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153-5. http://dx.doi.org/10.1016/j.cmet.2006.01.004.
65. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987;84:3434-8. http://dx.doi.org/10.1073/pnas.84.10.3434.
66. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004;47:806-15. http://dx.doi.org/10.1007/s00125-004-1379-6.
67. Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 2002;143:3152-61. http://dx.doi.org/10.1210/en.143.8.3152.
68. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003;144:5149-58. http://dx.doi.org/10.1210/en.2003-0323.
69. Portha B, Tourrel-Cuzin C, Movassat J. Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. Exp Diabetes Res 2011;2011:376509.
70. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes 2010;59:1117-25. http://dx.doi.org/10.2337/db09-1899.
71. Vilsbøll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 2004;47:357-66. http://dx.doi.org/10.1007/s00125-004-1342-6.
72. Cernea S. The role of incretin therapy at different stages of diabetes. Rev Diabet Stud 2011;8:323-38. http://dx.doi.org/10.1900/RDS.2011.8.323.
73. Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, Suzuma K, et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 2007;56:1551-8. http://dx.doi.org/10.2337/db06-1033.
74. Kubota A, Yamada Y, Hayami T, Yasuda K, Someya Y, Ihara Y, et al. Identification of two missense mutations in the GIP receptor gene: a functional study and association analysis with NIDDM: no evidence of association with Japanese NIDDM subjects. Diabetes 1996;45:1701-5. http://dx.doi.org/10.2337/diabetes.45.12.1701.
75. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011;54:10-8. http://dx.doi.org/10.1007/s00125-010-1896-4.
76. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95. http://dx.doi.org/10.2337/db09-9028.
77. Schauer IE, Snell-Bergeon JK, Bergman BC, Maahs DM, Kretowski A, Eckel RH, et al. Insulin Resistance, Defective Insulin-Mediated Fatty Acid Suppression, and Coronary Artery Calcification in Subjects With and Without Type 1 Diabetes. The CACTI Study. Diabetes 2011;60:306-14. http://dx.doi.org/10.2337/db10-0328.
78. Cobelli C, Toffolo GM, Dalla Man C, Campioni M, Denti P, Caumo A, et al. Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 2007;293:E1-15. http://dx.doi.org/10.1152/ajpendo.00421.2006.
79. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003;46:3-19.
80. Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring) 2008;16:1901-7. http://dx.doi.org/10.1038/oby.2008.307.
81. Bergman RN, Ader M, Huecking K, Van Citters G. Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 2002;51 Suppl 1:S212-20. http://dx.doi.org/10.2337/diabetes.51.2007.S212.
82. Ahrén B, Pacini G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol 2004;150:97-104. http://dx.doi.org/10.1530/eje.0.1500097.
83. Mari A, Pacini G. Methods for the Assessment of β-cell Function in vivo. In Michael Roden ed. Clinical Diabetes and Research: Methods and Techniques. John Wiley & Sons Ltd.,2007.p. 7-27. http://dx.doi.org/10.1002/9780470513095.ch2.
84. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008;294:E15-26. http://dx.doi.org/10.1152/ajpendo.00645.2007.
85. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E. Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 2002;283:E1159-66.
86. Ferrannini E, Mari A. Beta cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia 2004;47:943-56. http://dx.doi.org/10.1007/s00125-004-1381-z.
87. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36 Suppl 1:S11-66. http://dx.doi.org/10.2337/dc13-S011.
88. Rodríguez-Cabaleiro D, Van Uytfanghe K, Stove V, Fiers T, Thienpont LM. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Pilot study for the standardization of insulin immunoassays with isotope dilution liquid chromatography/tandem mass spectrometry. Clin Chem 2007;53:1462-9. http://dx.doi.org/10.1373/clinchem.2007.088393.
89. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96. http://dx.doi.org/10.1007/s00125-012-2534-0.
90. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996;45:622-6. http://dx.doi.org/10.2337/diabetes.45.5.622.
91. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-60. http://dx.doi.org/10.1016/S0140-6736-(08)60762-X.
92. Argoud GM, Schade DS, Eaton RP. Insulin suppresses its own secretion in vivo. Diabetes 1987;36:959-62. http://dx.doi.org/10.2337/diabetes.36.8.959.
93. Jansen A, Rosmalen JG, Homo-Delarche F, Dardenne M, Drexhage HA. Effect of prophylactic insulin treatment on the number of ER-MP23+ macrophages in the pancreas of NOD mice. Is the prevention of diabetes based on beta-cell rest? J Autoimmun 1996;9:341-8. http://dx.doi.org/10.1006/jaut.1996.0046.
94. Hanefeld M. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. Int J Clin Pract Suppl 2007;61:20-7. http://dx.doi.org/10.1111/j.1742-1241.2007.01361.x.
95. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004;47:806-15. http://dx.doi.org/10.1007/s00125-004-1379-6.
96. Molavi B, Rassouli N, Bagwe S, Rasouli N. A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Vasc Health Risk Manag 2007;3:967-73.
97. Deans KA, Sattar N. "Anti-inflammatory" drugs and their effects on type 2 diabetes. Diabetes Technol Ther 2006;8:18-27. http://dx.doi.org/10.1089/dia.2006.8.18.
98. Tooley JE, Waldron-Lynch F, Herold KC. New and future immunomodulatory therapy in type 1 diabetes. Trends Mol Med 2012;18:173-81. http://dx.doi.org/10.1016/j.molmed.2012.01.001.
99. Aston-Mourney K, Hull RL, Zraika S, Udayasankar J, Subramanian SL, Kahn SE. Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets. Diabetologia 2011;54:1756-65. http://dx.doi.org/10.1007/s00125011-2143-3.
100. Hofsø D, Jenssen T, Bollerslev J, Ueland T, Godang K, Stumvoll M, et al. Beta cell function after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol 2011;164:231-8. http://dx.doi.org/10.1530/EJE-10-0804.